36 studies found for:    " September 15, 2010":" October 15, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 15, 2010":" October 15, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Conditions: Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:
2 Recruiting Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients
Condition: HIV Positive Patient Receive Implant Supported Restoration
Intervention:
3 Recruiting Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort
Conditions: HIV;   AIDS
Intervention:
4 Active, not recruiting Multi-vitamins, HAART and HIV/AIDS in Uganda
Condition: HIV/AIDS
Intervention: Dietary Supplement: Multivitamin supplements B,C and E
5 Recruiting R5 Integrase Study in HIV-1 Naive Patients
Condition: HIV Infections
Intervention: Drug: Raltegravir and Maraviroc in combination
6 Recruiting A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
7 Recruiting HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
8 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
9 Unknown  Measurement of Plasma and Intracellular Concentrations of Raltegravir
Condition: HIV
Intervention: Drug: Raltegravir
10 Completed Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
11 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
12 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
13 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
14 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
15 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
16 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
17 Recruiting Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
18 Active, not recruiting A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: raltegravir;   Other: Placebo;   Other: ABC/3TC;   Other: TDF/FTC
19 Recruiting Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
20 Recruiting Cohort of Young Adults Infected With HIV Since Birth or During Childhood
Conditions: HIV Infection;   Young Adult
Intervention: Biological: blood sampling, specific biological exams and biobank and self administered questionnaires

Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results
Indicates status has not been verified in more than two years